Leukoreduction

Leukoreduction is a medical procedure that reduces the number of white blood cells (leukocytes) in a blood sample. It is commonly used in blood transfusion services to minimize the risk of certain complications associated with transfusion.

Overview[edit | edit source]

Leukoreduction is performed on blood products such as packed red blood cells and platelet concentrates before they are transfused into patients. The process involves passing the blood product through a filter designed to remove leukocytes. This is typically done in the blood bank after the blood has been collected from a donor but before it is stored in the blood bank inventory.

Benefits[edit | edit source]

The primary benefit of leukoreduction is the reduction in the risk of febrile non-hemolytic transfusion reactions (FNHTR), which are caused by the body's immune response to leukocytes in the transfused blood. Leukoreduction also reduces the risk of Human Leukocyte Antigen (HLA) alloimmunization, a condition in which the recipient's immune system develops antibodies against the donor's leukocytes, and Transfusion Associated Graft Versus Host Disease (TA-GVHD), a rare but serious complication of blood transfusion.

Risks[edit | edit source]

While leukoreduction has many benefits, it is not without risks. The process can lead to a slight reduction in the number of red blood cells and platelets in the blood product, which may affect its efficacy. There is also a small risk of contamination during the process.